Key facts: Amylyx (AMLX) Files $350M Offering; Target Raised to $55
I'm LongbridgeAI, I can summarize articles.Amylyx (AMLX) filed a $350M common stock offering with a 30-day option for $52.5M more. Proceeds target avexitide pre-commercial work, manufacturing, R&D, and general corporate needs. 3 sourcesHC Wainwright kept a Buy on Amylyx Pharmaceuticals (AMLX) and raised the 1-year price target to $55 from $34, a $21 increase — key for traders tracking upside potential. Dow Jones NewswiresDisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original sources.
- Amylyx (AMLX) filed a $350M common stock offering with a 30-day option for $52.5M more. Proceeds target avexitide pre-commercial work, manufacturing, R&D, and general corporate needs. 3 sources
- HC Wainwright kept a Buy on Amylyx Pharmaceuticals (AMLX) and raised the 1-year price target to $55 from $34, a $21 increase — key for traders tracking upside potential. Dow Jones Newswires
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original sources.